Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228.
Published September 2, 2026 · Recall initiated: August 24, 2026
Summary
FDA records drug Class II recall D-0831-2026, published September 2, 2026 and initiated August 24, 2026. Recalling firm: Hikma Pharmaceuticals USA INC.; Status: Ongoing; Reported quantity: a) 25,970 bottles; b) 2,384 bottles; Lot: a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
What to do
Voluntary: Firm initiated · Letter
Get an email if RAMIPRIL has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- RAMIPRIL
- Manufacturer
- Hikma Pharmaceuticals USA INC.
- Distributor
- Nationwide within the United States
- UPC
- 0376282670010
- Lot
- a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDATyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by FreseniusSeptember 2, 2026
- FDALactated Ringer's Injection USP, 1000 mL EXCEL container, Rx only, L7500, B. Braun Medical, Inc., Bethlehem,September 2, 2026
- FDAPaxil CR, Paroxetine, Extended-Release Tablets, 37.5mg, 30 count bottle, Rx only, Manufactured by: ApotexSeptember 2, 2026
- FDARamipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC 68180-591-01), and c) 500 countNovember 27, 2024
- FDARamipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 countNovember 27, 2024
- FDARamipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 countNovember 27, 2024
Questions about this recall
Was Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228. recalled?
Yes. FDA published recall D-0831-2026 on September 2, 2026. Reported hazard: Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: RAMIPRIL. UPC: 0376282670010.